Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: A

Drug products: Apixaban Teva GmbH, Eliquis

ATC code: B01AF02

Substances: apixaban


Apixaban reduces the risk of stroke and systemic embolism as effectively in men as in women with atrial fibrillation. The effect of apixaban as initial treatment and as prophylaxis of recurrent venous thromboembolism is similar in men and women. The risk of larger bleeds is similar in men and women.

Additional information

Pharmacokinetics and dosing

The exposure of apixaban is reported to be about 18% higher in women than men [12]. However, a study of healthy individuals (40 men, 40 women) receiving a single dose of apixaban 20 mg reported no significant differences between men and women in Cmax and AUC of apixaban [13]. No dose adjustment based on sex is recommended [12].


New oral anticoagulantsIn atrial fibrillation (AF) patients, large meta-analyses of phase III trials have found that NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are better than warfarin in preventing stroke and systemic embolism in both men and women [1-3]. In contrast, a meta-analysis on data from other phase III trials (in total 18 415 men, 13 094 women) on NOACs (apixaban, dabigatran, ximelagatran), found that men were more protected from stroke or systemic embolism than women [4]. An observational study on AF patients in Hong-Kong (4972 men, 4834 women) showed that use of NOACs (apixaban, dabigatran, rivaroxaban) was associated with lower all-cause mortality in women but not in men, when compared to warfarin [5]. However, risk of stroke and response to thrombolytic therapy may vary between ethnic groups, and a higher risk of bleeding in Asians treated with warfarin has been reported [5]. Similarly, another meta-analysis found a higher risk of stroke and systemic embolism in women treated with NOAC (apixaban, dabigatran, edoxaban, rivaroxaban) [6].In venous thromboembolism (VTE) patients, two sex-specific meta-analyses on NOACs (apixaban, dabigatran, edoxaban, rivaroxaban, ximelagatran) have found no sex difference in the rate of VTE recurrence [7, 8]. Specific for apixabanThe pivotal studies in AF patients, ARISTOTLE and AVERROES, show similar treatment effects of apixaban in men and women [14, 15]. In the large ARISTOTLE study (11785 men, 6416 women), patients received either apixaban 5 mg twice daily or dose-adjusted warfarin. Efficacy for apixaban in subgroups, such as age and patient’s sex, were equally consistent with the primary efficacy results for the whole study population [14, 16]. The AVERROES study (3277 men, 2322 women) compared efficacy of apixaban (5 mg twice daily) with aspirin (81-324 mg daily) in the treatment of patients with AF for whom vitamin K antagonist therapy was considered unsuitable. The positive benefit of apixaban was equal in men and women [15].The pivotal VTE studies, AMPLIFY and AMPLIFY-EXT, report similar treatment effects of apixaban in men and women [17, 18]. In the AMPLIFY study (3169 men, 2226 women), standard dosing of apixaban was compared with enoxaparin/warfarin in patients with acute VTE. Relative risks of recurrent symptomatic VTE or death related to VTE were similar in men and women [17]. In AMPLIFY-EXT (1424 men, 1058 women), apixaban in two doses (2.5 mg and 5 mg, twice daily) were compared with placebo in patients who had completed participation in the AMPLIFY study or had been treated for 6-12 months with standard anticoagulant therapy. Relative risks of symptomatic recurrent VTE or all-cause death were similar for all doses of apixaban [18].

Adverse effects

New oral anticoagulantsA sex-specific meta-analysis on the risk of bleeding from anticoagulants in patients with AF or VTE (57 043 men, 37 250 women) found a similar bleeding risk in men and women [9]. However, sex differences have been observed when analyzing by indication, as described below.In AF patients, a worldwide meta-analysis (16 760 men, 9 500 women) found that women treated with NOACs (apixaban, dabigatran, rivaroxaban) had lower risk of major bleeding than men, while women treated with warfarin had similar risk of bleeding as men [2]. Similarly, another meta-analysis found a lower risk of major bleeding in women (apixaban, dabigatran, edoxaban, rivaroxaban) even after omitting the AVERROES study using aspirin as comparator [6]. Contrary to this, another meta-analysis, including the same studies, found no sex differences in major bleeding events from NOACs (apixaban, edoxaban, dabigatran, rivaroxaban), when compared with warfarin [3]. Also, an observational study conducted in Hong-Kong (4972 men, 4834 women) showed that use of NOAC (apixaban, dabigatran, rivaroxaban) was associated with a lower risk of intracranial hemorrhage in women but not in men, when compared with warfarin. The risk of GI bleeding was similar in men and women treated with NOAC, when compared with warfarin [5].In VTE patients, a sex-specific meta-analysis (43.7% women) found that women had more bleeding events from NOACs (apixaban, rivaroxaban, ximelagatran) than men [7]. Another sex-specific meta-analysis on VTE (13 139 men, 9814 women) found a higher risk of bleeding in women than in men from both warfarin and NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) [10]. However, another similar meta-analysis of the same studies showed that the sex difference in incidence of bleedings was only significant for edoxaban (RR 0.52) [8, 11]. Specific for apixabanThe pivotal studies of apixaban report that the risks of major bleeding in men and women are consistent with the primary safety results of the whole study populations. In AF patients, the relative risks of major bleeding were similar in men and women [14].In VTE patients, the relative risks of major bleeding were 0.38 for men and 0.24 for women in the AMPLIFY study [17]. No sex-divided data of the primary safety outcome major bleeding was presented in AMPLIFY-EXT. The relative risks of secondary safety outcome (composite of major and clinically relevant non-major bleeding) were similar in men and women [18].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2022-10-25

Date of litterature search: 2018-11-12


  1. Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther. 2012;10(12):1471-80. PubMed
  2. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014;113(3):485-90. PubMed
  3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. PubMed
  4. Proietti M, Cheli P, Basili S, Mazurek M, Lip GY. Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences. Pharmacol Res. 2017;117(1):274-282. PubMed
  5. Law SWY, Lau WCY, Wong ICK, Lip GYH, Mok MT, Siu CW et al. Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018;72(3):271-282. PubMed
  6. Raccah BH, Perlman A, Zwas DR, Hochberg-Klein S, Masarwa R, Muszkat M et al. Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis. Ann Pharmacother. 2018;52(11):1135-1142. PubMed
  7. Alotaibi GS, Almodaimegh H, McMurtry MS, Wu C. Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis. Thromb Res. 2013;132(2):185-9. PubMed
  8. Loffredo L, Violi F, Perri L. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants A meta-analysis of the interventional trials. Int J Cardiol. 2016;212:255-8. PubMed
  9. Lapner S, Cohen N, Kearon C. Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(5):595-605. PubMed
  10. Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014;134:774-82. PubMed
  11. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-15. PubMed
  12. Eliquis (apixaban). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2018-03-09, cited 2018-11-12].
  13. Frost CE, Nepal S, Barrett Y, LaCreta F. Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. Journal of Thrombosis and Haemostasis. 2009;7:(Suppl s2). PubMed
  14. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. PubMed
  15. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17. PubMed
  16. Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC et al. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015;36(46):3268-75. PubMed
  17. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. PubMed
  18. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. PubMed
  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-06.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson